ALXO
Alx Oncology Holdings Inc

1,265
Mkt Cap
$276.83M
Volume
657,968.00
52W High
$2.66
52W Low
$0.404
PE Ratio
-1.04
ALXO Fundamentals
Price
$2.12
Prev Close
$2.11
Open
$2.02
50D MA
$1.70
Beta
1.42
Avg. Volume
348,234.90
EPS (Annual)
-$1.90
P/B
2.52
Rev/Employee
$0.00
$23.65
Loading...
Loading...
News
all
press releases
ALX Oncology (NASDAQ:ALXO) Posts Earnings Results
ALX Oncology (NASDAQ:ALXO - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.04...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
ALX Oncology Q4 Earnings Call Highlights
ALX Oncology (NASDAQ:ALXO) outlined progress across its two core programs CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate ALX2004 while providing updated clinical timelines and...
MarketBeat·3d ago
News Placeholder
A Look Ahead: ALX Oncology Holdings's Earnings Forecast
read more...
Benzinga·4d ago
News Placeholder
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
Zacks·5d ago
News Placeholder
ALX Oncology (ALXO) Expected to Announce Earnings on Friday
ALX Oncology (NASDAQ:ALXO) will be releasing its Q4 2025 earnings before the market opens on Friday, February 27. (View Earnings Report at...
MarketBeat·9d ago
News Placeholder
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Zacks·21d ago
News Placeholder
Insider Buying: ALX Oncology (NASDAQ:ALXO) Director Purchases $4,999,999.41 in Stock
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) Director Corey Goodman bought 3,184,713 shares of ALX Oncology stock in a transaction that occurred on Monday, February 2nd. The stock was...
MarketBeat·25d ago
News Placeholder
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the firm, Marketbeat reports...
MarketBeat·1mo ago
News Placeholder
ALX Oncology Spotlights Evorpacept HER2 Strategy and EGFR ADC ALX2004 Progress at JPM Conference
ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate (ADC) ALX2004 during a presentation at the J.P...
MarketBeat·2mo ago
News Placeholder
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages
ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat...
MarketBeat·2mo ago
<
1
2
...
>

Latest ALXO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.